Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Research Paper

Japanese encephalitis virus: A multi-epitope loaded peptide vaccine formulation using reverse vaccinology approach

Supriyo Chakraborty⁎, Antara Barman, Bornali Deb

Department of Biotechnology, Assam University, Silchar 788011, Assam, India

ARTICLE INFO

Keywords:
JEV
T-cell epitope
B-cell epitope
Peptide vaccine

ABSTRACT

Japanese encephalitis (JE) is a serious leading health complication emerging expansively that has severely affected the survival rate of human beings. This fatal disease is caused by JE Virus (JEV). The current study was carried out for designing a multi-epitope loaded peptide vaccine to prevent JEV. Based on reverse vaccinology and in silico approaches, octapeptide B-cell and hexapeptide T-cell epitopes belonging to five proteins, viz. E, prM, NS1, NS3 and NS5 of JEV were determined. Hydrophilicity, antigenicity, immunogenicity and aliphatic amino acids of the epitopes were estimated. Further, the epitopes were analyzed for different physicochemical parameters, e.g. total net charges, amino acid composition and Boman index. Out of all the epitopes, a total of four T-cell epitopes namely KRADSS, KRSRRS, SKRSRR and KECPDE and one B-cell epitope i.e. PKPCSKGD were found to have potential for raising immunity in human against the pathogen. Taking into account the outcome of this study, the pharmaceutical industries could initiate efforts to combine the identified epitopes together with adjuvant or carrier protein to develop a multi-epitope-loaded peptide vaccine against JEV. The peptide vaccine, being cost effective, could be administered as a prophylactic measure and in JEV infected individuals to combat the spread of this virus in human population. However, prior to administration into human beings, the vaccine must pass through several clinical trials.

1. Introduction

Japanese encephalitis (JE) is a major emerging, dreadful infection worldwide as this fatal disease has affected the lives of many individuals resulting into 15,000 deaths and 50,000 cases of infection per year (Solomon, 1997; Tsai, 1997). The causal agent of the disease is JE virus (JEV). JEV is transmitted by mosquitoes and is categorized into genus Flavivirus and family Flaviviridae (Westaway et al., 1985). JEV severely affects the central nervous system of humans and results into infectious disease. The transmission cycle of JEV occurs between mosquitoes and birds or swine. However, the transmission of the virus to humans usually takes place through infected mosquitoes of the species, Culex tritaeniorrhynchus (Porterfield, 1995). JEV is found to prevail in many Asian nations namely India, Nepal, Sri Lanka, China, Japan, Korea, Vietnam, Thailand, Myanmar, Taiwan, Siberia, Cambodia, Bhutan, Bangladesh, Malaysia and Indonesia. The JE epidemic has spread from Eastern Asia to Southeast and Southern Asia (Burke and Leake, 1988b; Oya, 1988; Vaughn and Hoke Jr, 1992; Endy and Nisalak, 2002; Mackenzie et al., 2006). Apart from Asia, JEV has affected many geographic regions of other continents as well, namely Northern Australia and Western Pacific (Paul et al., 1993; Hanna et al., 1996; Hanna et al., 1999). The outbreak of JE was first observed in Japan during 1870s and the first isolate of JEV was obtained by culturing the brain cells of an infected individual in 1935 (Solomon et al., 2000).

Although children are the primary targets of JE infection, it also causes dreadful infection in adolescents and adults. In temperate regions of Asia JE outbreaks mainly occur in summer; while outbreaks in torrid zone and subtropics of Asia prevail throughout the year and the occurrence of JE infections rapidly increases during rainy days (Burke and Leake, 1988b; Halstead and Jacobson, 2008; Fischer et al., 2010). Symptoms of JEV infection include fever, meningitis, seizures or poliomyelitis-like paralysis (Solomon et al., 1998; Solomon et al., 2002; Solomon and Vaughn, 2002). Death occurs in about 20–30% of JE infected cases and about 30–50% of surviving people usually encounter constant abnormalities associated with nervous system, e.g. mental disorientation, mental retardation and hemiparesis (Solomon et al., 2000; Fischer et al., 2008; Ooi et al., 2008).

There are five different genotypes of JEV (Uchil and Satchidanadam, 2001; Solomon et al., 2003) and all the strains belong to only one serotype (Tsarev et al., 2000; Erra and Kantele, 2015). JEV genome consists of a positive-sense single stranded RNA molecule of
The current study was performed for predicting the potential T-cell and B-cell epitopes of five proteins in JEV namely E, prM, NS1, NS3 and NS5 of JEV for designing a multi-epitope loaded peptide vaccine. This study allows the identification of unique peptides as vaccine candidates that might be much cheaper than the existing vaccine formulation against JEV. Our analysis suggested that E, prM and NS1 proteins possess capability for generating immunological response in the host body (Monath et al., 1996). Another study reported that NS3 and NS5 proteins can induce immune reaction in the host body (Turtle et al., 2016). The predicted epitopes identified in five proteins selected in this study could be promising for formulating a peptide vaccine against JEV and hence, could prevent the spread of JEV in affected individuals.

2. Materials and methods

2.1. Extraction of protein sequences

Complete sequences of the proteins, viz. E, prM, NS1, NS3 and NS5 of JEV were collected from the Protein database of National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov). All the proteins were identified to possess their respective accession numbers: NP_775666.1, NP_775664.1, NP_775667.1, NP_775670.1 and NP_775674.1.

2.2. Determination of T-cell epitopes

Using the algorithm based on wet lab experiments and established by Hopp and Woods, the linear hexamer T-cell epitopes in five selected proteins of JEV were identified (Hopp and Woods, 1981). Further, the set of linear octamer B-cell epitopes in five selected JEV proteins was determined by using the algorithm outlined by Kolaskar and Tongaonkar (Kolaskar and Tongaonkar, 1990).

2.3. Determination of hydrophilicity score

Hydrophilicity score is a measure that describes the hydrophilicity of an epitope or a protein. It is the mean of the hydrophilicity values of all the amino acids contained in an epitope or a protein. It is useful in determining the structure of the protein (Hopp and Woods, 1981).

2.4. Hydropathy index

Hydropathy index, a measure of hydrophobicity of a given epitope or a protein, was determined as the average of hydrophobicity values from all amino acids present in an epitope or a protein (Kyte and Doolittle, 1982). Estimation of Hydropathy index values of all epitopes was achieved by applying the AbDesigner algorithm (Pisitkun et al., 2011).

2.5. Chou-Fasman conformation

Beta-turn regions within a protein have significant role in generating immunogenicity. Chou-Fasman algorithm was used to determine the properties of secondary structure of peptide (Chou and Fasman, 1978).

2.6. Immunogenicity score

Immunogenicity score reports the immunogenic nature of a given epitope or protein. The immunogenicity scores of all the epitopes were estimated on the basis of hydropathy index and Chou-Fasman conformation parameters of each epitope. Further, hydrophilicity, antigenicity and immunogenicity scores as well as aliphatic amino acids in each epitope were estimated using a computer program written in PERL language by SC (corresponding author).
2.7. Determination of physicochemical parameters of epitopes

The physico-chemical parameters of epitopes such as net charge and amino acid composition were determined in ProtParam tool of ExpASy (https://web.expasy.org/protparam/). Further, the cleavage sites in epitopes were identified using the online tool Peptide cutter (https://web.expasy.org/peptide_cutter/) (shown in S1 and S2). Boman index i.e. the protein binding potential of each epitope was determined by using the online tool APD3 i.e. (http://aps.unmc.edu/AP/prediction/prediction_main.php). The epitopes that acquire Boman index values higher than 2.48 kcal/mol are considered being capable of attaching to the MHC molecules or antibodies.

3. Results

3.1. Hydrophilicity scores of epitopes

With the help of bioinformatic tools, five hexapeptide T-cells epitopes and five octapeptide B-cell epitopes were identified in five proteins namely E, prM, NS1, NS3 and NS5 of JEV.

In order to combat the spread of JEV, hexapeptide T-cell epitopes would possess the ability to raise high immune response in the host (Hopp and Woods, 1981). The epitope positions, hydrophilicity scores and total net charges of all T-cell epitopes were determined (Table 1a). Out of five epitopes in E protein, the epitope EKRADS (epitope position 83–88) was recorded with the greatest hydrophilicity score (11.8) but without any net charge. Two epitopes namely KRSSRS (epitope position 88–93) and KRSSRR (epitope position 87–92) located within prM protein exhibited the greatest hydrophilicity value (12.6) with positive net charge (+4). Similarly, within NS1 protein, two epitopes with maximum hydrophilicity score of 11.9 were identified as EESTDE (173–178) and REESTD (172–177) carrying net charges of −4 and −2, respectively. The epitope RGEEKK (527–532) of NS3 protein was estimated with the highest hydrophilicity value (15) along with a positive net charge (+3). High hydrophilicity scores of T-cell epitopes along with their positions usually represent the hydrophilic sections in proteins and these regions tend to remain exposed on the surface of the proteins. These regions can bind easily with the MHC molecules and the complexes so formed would be exhibited by the APCs on their surfaces. The T-cells can easily recognize these cells and destroy them.

The epitope positions, hydrophilicity scores and total net charge of each octapeptide B-cell epitope were evaluated (Table 1b). In E protein, the epitope SSGDGC (329–336) occupied maximal hydrophilicity value (5.6) but without any net charge. In the case of prM protein, two epitopes namely SKRSGRSV (87–94) and SKRSGRSVS (88–95) were identified with the highest hydrophilicity score of 11.4 with net charge of +4 each. In NS1 protein, the epitope TKECPDEH (140–147) was recorded with the highest hydrophilicity value (10.4) and a negative net charge (−2). In NS3 protein, the epitope PKPCKGD (10–17) was found to possess high hydrophilicity value (8.3) with a positive net charge (+1). In NS5 protein, the epitope PYVKGRED (842–849) was found to possess the highest hydrophilicity score of 8.2 without any net charge. High hydrophilicity scores of B-cell epitopes imply that these epitopes lie in the hydrophilic regions of the respective proteins and can interact with the antibodies produced by B-cells. This interaction might lead to the generation of immunological response in host against JEV.

3.2. Antigenicity scores of epitopes

All T-cell epitopes obtained from five proteins were examined and evaluated for antigenicity (Fig. 1 a). Antigenicity values of the 25 T-cell epitopes were found to range from 5.07 (DEEREN) to 5.97 (KECPDE). Likewise, total 25 B-cell epitopes were also analyzed for antigenicity score (Fig. 1b) and the antigenicity scores of B-cell epitopes varied from 7.97 (SKRSGRSV, KRGRGWSY) to 8.49 (PSPKPCSK). The epitopes possessing high antigenicity values normally represent highly antigenic nature of the epitopes. Notably, high antigenicity score of an epitope is treated as a salient feature for the formulation of a peptide vaccine.

3.3. Immunogenicity scores of epitopes

Like antigenicity analysis, all the hexapeptide T-cell epitopes were evaluated for their immunogenicity scores (Table 2a). In E protein, the epitope NARDS was found to possess the highest immunogenicity score (8.19) whereas, in prM protein the epitope GNPED recorded

| Table 1a | T-cell epitopes from five proteins of JEV representing their hydrophilic scores and total net charges (Hopp & Woods approach, 1981). |
|------------------------|-----------------------------------------------|
| Name of virus | Name of proteins | Accession number | Hexapeptide epitope | Epitope position | Hydrophilicity score | Total net charge |
| Japanese encephalitis | E protein | NP_775666.1 | EKRADS | 83–88 | 11.8 | 0 |
| | prM protein | NP_775664.1 | KRSSRS | 88–93 | 12.6 | 4 |
| | NS1 protein | NP_775667.1 | EESTDE | 173–178 | 11.9 | −4 |
| | NS3 protein | NP_775670.1 | RGEKK | 527–532 | 15 | 1 |
| | NS5 protein | NP_775674.1 | DEEREN | 438–443 | 15.2 | −3 |
Six epitopes were identified from the protein, and KREKKP of NS5 protein had 3 aliphatic amino acids each. Epitopes, namely GRGDKQ of E protein, RGEEKK and GEEKKN of NS3 protein, and DRQEEP of NS3 protein consisted of 4 aliphatic amino acids. Four epitopes, viz. DEEREN and REKRPR each possessed the highest immunogenicity score viz. 8.39. But in NS3 protein the epitope DRQEEP was found to possess the highest immunogenicity score as well as the number of aliphatic amino acids contained in each epitope. In NS1 protein, the epitope HKDPEHPY recorded the maximum immunogenicity score of 7.14. Further, in NS3 protein the epitope YPKCKNGD recorded with maximal immunogenicity score (7.5).

B-cell epitopes were determined (Table 2b). In E protein the epitope HKDPEHPY recorded the maximum immunogenicity score (9.89). In NS1 protein the epitope KHNRRE was identified with the highest immunogenicity score (8.6) but in NS3 protein the epitope DRQEEP was found to possess the maximum immunogenicity score of 8.4. In NS5 protein two epitopes, viz. DEEREN and REKRPR each possessed the highest immunogenicity score (8.42).

Aliphatic amino acid plays an important role in binding affinity. It is believed that the epitopes comprising of aliphatic amino acids viz. Ala, Gly, Ile, Lys, Leu, Met and Val can interact easily with either of the two lymphocytes. In the present study, the T-cell epitopes were examined to calculate their aliphatic amino acid number (Table 2a). One epitope, GKEKKK of NS5 protein consisted of 4 aliphatic amino acids. Four epitopes, namely GRGDKQ of E protein, RGEEKK and GEE kneK of NS3 protein, and KREKKP of NS5 protein had 3 aliphatic amino acids each. Six epitopes were identified to consist of 2 aliphatic amino acids namely EKRADS, NEKRAD and KRADSS of E protein; SKGENR of prM protein; EDGCKR of NS1 protein; and GPEREK of NS3 protein. Ten epitopes, i.e. NARDRS of E protein; KRSSHSSS, KRSSHSSR, DPRPVD and GNPDD of prM protein; KHNRRE and KECPEDE of NS1 protein; GDRQEE of NS3 protein; and REKRPR and RRARRE of NS5 protein contained a single aliphatic amino acid. However, four epitopes were identified with no aliphatic amino acid and these were EESTDE and REESTD of NS1 protein, DRQEEP of NS3 protein, and DEEREN of NS5 protein.

In the case of all octapeptide B-cell epitopes, the immunogenicity score as well as the number of aliphatic amino acids contained in each B-cell epitope were determined (Table 2b). In E protein the epitope YSGSDGPKC was identified to possess the highest immunogenicity score of 7.46 whereas, in prM protein the epitope NPDPEDVDC was recorded with maximal immunogenicity score (7.5). In NS1 protein the B-cell epitope TKECPDEH was estimated with maximum immunogenicity score of 7.14. Further, in NS3 protein the epitope YPKCKNGD recorded the highest immunogenicity score (8.45) whereas, in NS5 protein the epitope HKDPEHPY recorded the maximum immunogenicity score of 8.39. Nine epitopes namely SGSDGPKC and LSYS GSDG of E protein; KPVGRYRS of NS1 protein; YPKCKNGD, PKPCSKGD and EYPKCKNG of NS3 protein; GKENYDVi, PYVGKR EDE and CGRGGWSY of NS5 protein were identified to contain 3 aliphatic amino acids. Seven epitopes were found to possess 2 aliphatic amino acids i.e. YSGSDGPC and ELSYS GSDG of E protein, KR SRRSV and KR SRRSVS of prM protein, DRYKL YLPE and KYPK PETPR of NS1 protein and PS PKPCSK of NS3 protein. Seven epitopes, i.e. EPPFGDSY of E protein, NPDPEDVDC of prM protein, TKECPDEH and ECPDEHRA of NS1 protein, DTPSPKPC of NS3 protein, and HKDPEHPY and FYKPS EPS of NS5 protein contained a single aliphatic amino acid. Moreover, two epitopes namely DCWCDNQE and RCTRTRHS of NS5 protein contained no aliphatic amino acid. It is believed that the epitopes that possess high immunogenicity score are highly immunogenic and the immunogenicity score of a peptide epitope is a determining factor in choosing epitopes for peptide vaccine formulation.

### 3.4. Boman index of epitopes

Boman index values of all hexapeptide T-cell epitopes present in five JEV proteins were estimated (Fig. 2a). We used Boman value 2.48 kcal/mol as the minimum cut-off value. Notably, all the 25 T-cell epitopes in our study possessed Boman value > 2.48 kcal/mol and were considered to have potential for binding successfully to MHC molecules. From these results we concluded that the complexes would be presented to T-cells by APCs and would elicit immune response in the host. Further, we noted that the Boman index of T-cell epitopes ranged from 4.43 (KECPDE) to 10.78 (RRARRE).

Similarly, we estimated Boman index of all the 25 B-cell epitopes (Fig. 2b). Eight B-cell epitopes, viz. SGSDGPKC, YSGSDGPC, EPPFDGY DS and LSYS GSDG of E protein; PS PKPCSK and DTPSPKPC of NS3 protein; and FYKPS EPS and CGRGGWSY of NS5 protein were found to have Boman index < 2.48 kcal/mol which indicated they may not attach to immunoglobulins secreted by B-cells. The remaining epitopes possessed Boman index > 2.48 kcal/mol and hence, these epitopes could bind to immunoglobulins effectively.

### 3.5. Amino acid composition of epitopes

The T-cell epitopes of JEV proteins were analyzed for their amino acid arrangement (Fig. 3a). Different amino acids were found in epitopes. Interestingly, some epitopes of E, prM, NS1 and NS3 proteins comprised of amino acids like Lys, Asp, Gly, Ser, Glu, Arg constituting nearly 33.30% of the total composition. On the other hand, some...
epitopes of prM, NS3 and NS5 proteins contained Arg, Asp, Glu and Lys to the extent of 50.00%. Only one epitope RRARRE of NS5 protein was found to contain Arg constituting 66.70% of the total epitope composition.

Likewise, the B-cell epitopes of JEV proteins were analyzed for amino acid composition (Fig. 3b). All the epitopes contained varying amino acid composition. Some B-cell epitopes contained amino acids namely Tyr, His, Asp, Ser, Gly, Lys, Thr, Cys, Glu, Pro and Arg constituting nearly 25.00% of the total composition. Further, some other epitopes of E, prM, NS3 and NS5 proteins were found to possess Ser, Gly, Arg, Pro and Asp constituting 37.50% of the total epitope composition.

Further, the T-cell and B-cell epitopes against JEV are amenable to cleavage by various enzymes and chemicals and the results of cleavage are presented in supplementary tables (S1, S2).

4. Discussion

In this study, the potential epitopes for peptide vaccine formulation were identified in five proteins of JEV namely E, prM, NS1, NS3 and NS5. All the epitopes were analyzed for various parameters using different bioinformatic tools. Only a few epitopes were found to possess the properties essential for generating immune response in the host against JEV and the selected epitopes might be used in formulating an effective peptide vaccine to combat the menace of JEV.

Earlier several studies were carried out by other researchers for designing peptide vaccine based on genome derived or reverse vaccinology approach. In a study conducted by Wei et al. (2010), the epitopes existing in E protein of JEV were identified that possessed the ability for developing peptide vaccine. Two T-cell epitopes were determined positioning at amino acid sequences 436–445 and 60–68, while six B-cell epitopes positioning at amino acid sequences 356–362, 75–92, 258–285, 149–163, 397–403, and 373–399 were identified (Wei et al., 2010).

Chikungunya infection, a viral disease spread by Aedes mosquitoes, is caused by Chikungunya virus (CHIKV). Kori et al. (2015) identified the epitopes from the proteins of three CHIKV strains having potential for peptide vaccine formulation. The T-cell epitopes identified by them included DAEKEAEEEREAELT, AEEEREAEL and KKKPGRRERMCMKIE whereas, the B-cell epitopes were found to be QVLKAKNIGL and
SSKYDLECAQ (Kori et al., 2015).

Zika virus (ZIKV) that causes deadly infectious disease results in malformed babies and the decline of survival rate in human. Yadav et al. (2017) identified epitopes in the envelope glycoprotein sequence of ZIKV that could be employed for creating a peptide vaccine to prevent ZIKV. The T-cell epitope YRIMLSVHG possessed the competence for developing immunity (Yadav et al., 2017).

Nipah virus (NiV) causes respiratory infection and encephalitis in human and the transmission usually occurs through pigs or bats. In order to design peptide vaccines for treatment of NiV diseases, two potential epitopes from NiV proteins i.e. Glycoprotein (G) and Fusion (F) protein were detected with the help of immunoinformatics approach. It was reported that either the epitope EWISIVPNFILVRNT from G-protein or the epitope GPKVSLIDTSSTI from F-protein could be used for vaccine development (Sakib et al., 2014).

High-risk human papillomavirus (hrHPVs) is known to cause viral infections as well as cervical cancers in human. In a study, the probable epitopes were identified from E6 protein of hrHPVs and these epitopes were reported to possess competence in preparing successful peptide vaccine against hrHPVs. Based on in silico approach, it was suggested

| Table 2a | Immunogenicity (Ig) and number of aliphatic amino acids in T-cell epitopes of JEV (Hopp & Woods approach, 1981). |
|-----------------------------|-------------------------------------------------|--------------------------------|-----------------------------|
| Name of virus | Name of proteins | Accession number | Hexapeptide epitope | Aliphatic amino acids | Ig analysis of hexapeptide epitopes |
|                |                   |                  |                   |                         | Hydrophathy index | Chou-Fasman conformation | Ig score |
| Japanese encephalitis | E protein | NP_775666.1 | EKRADS | 2 | 6.9 | 1.04 | 7.18 |
|                       |                   |                  | NEKRAD | 2 | 7.35 | 1.06 | 7.79 |
|                       |                   |                  | GGGDQK | 3 | 7.2 | 1.25 | 8 |
|                       |                   |                  | KRADSS | 2 | 6.45 | 1.16 | 7.48 |
|                       |                   |                  | NARDRS | 1 | 7 | 1.17 | 8.19 |
|                       |                   |                  | GNDPES | 1 | 7.17 | 1.38 | 9.89 |
|                       |                   |                  | PreM protein | NP_775664.1 | KQRSRS | 1 | 7.67 | 1.12 | 8.59 |
|                       |                   |                  | SKRSRR | 1 | 7.67 | 1.12 | 8.59 |
|                       |                   |                  | DPEPVD | 1 | 6.4 | 1.19 | 7.62 |
|                       |                   |                  | SKGREN | 2 | 7.27 | 1.21 | 8.8 |
|                       |                   |                  | GNDPES | 1 | 7.17 | 1.38 | 9.89 |
|                       |                   |                  | NS1 protein | NP_775667.1 | EESTOE | 0 | 7.08 | 1.01 | 7.15 |
|                       |                   |                  | REESTD | 0 | 7.25 | 1.05 | 7.61 |
|                       |                   |                  | KHRFRE | 1 | 8.35 | 1.03 | 8.6 |
|                       |                   |                  | EDCGKR | 2 | 6.72 | 1.15 | 7.73 |
|                       |                   |                  | KECPOE | 1 | 6.75 | 1.11 | 7.49 |
|                       |                   |                  | NS3 protein | NP_775670.1 | RGEKKK | 3 | 7.78 | 1 | 7.78 |
|                       |                   |                  | EGEKKN | 3.1 | 7.62 | 1.08 | 8.38 |
|                       |                   |                  | DRQEEP | 0 | 7.85 | 1.07 | 8.4 |
|                       |                   |                  | GDRQEE | 1 | 7.65 | 1.07 | 8.19 |
|                       |                   |                  | GPEREK | 2 | 7 | 1.09 | 8.07 |
|                       |                   |                  | NS5 protein | NP_775674.1 | DEEREN | 0 | 8.17 | 1.03 | 8.42 |
|                       |                   |                  | KRKEKP | 3 | 8.05 | 1.04 | 8.37 |
|                       |                   |                  | GKEKKE | 4 | 8.85 | 1.05 | 8.24 |
|                       |                   |                  | REKPRR | 1 | 8.25 | 1.02 | 8.42 |
|                       |                   |                  | RRARRR | 1 | 7.78 | 0.87 | 6.77 |

| Table 2b | Immunogenicity (Ig) and number of aliphatic amino acids in B-cell epitopes of JEV (Kolaskar & Tongaonkar approach, 1990). |
|-----------------------------|-------------------------------------------------|--------------------------------|-----------------------------|
| Name of virus | Name of proteins | Accession number | Octapeptide epitope | Aliphatic amino acids | Ig analysis of octapeptide epitopes |
|                |                   |                  |                   |                         | Hydrophathy index | Chou-Fasman conformation | Ig score |
| Japanese encephalitis | E protein | NP_775666.1 | SGSGPGCK | 3 | 5.61 | 1.39 | 7.8 |
|                       |                   |                  | YSGDGPGC | 2 | 5.29 | 1.41 | 7.46 |
|                       |                   |                  | EPPFDGY | 1 | 5.74 | 1.25 | 7.18 |
|                       |                   |                  | LSYGSDG | 3 | 5.03 | 1.33 | 6.69 |
|                       |                   |                  | ELSYSGSD | 2 | 5.41 | 1.22 | 6.6 |
|                       |                   |                  | PreM protein | NP_775664.1 | NPDEVDCC | 1 | 6.05 | 1.24 | 7.5 |
|                       |                   |                  | DCHCDQNE | 0 | 6.18 | 1.19 | 7.35 |
|                       |                   |                  | KRSRSSV | 2 | 6.45 | 1.08 | 6.97 |
|                       |                   |                  | RCRTRH | 2 | 6.45 | 1.08 | 6.97 |
|                       |                   |                  | NS1 protein | NP_775667.1 | TKECPDEH | 1 | 6.67 | 1.07 | 7.14 |
|                       |                   |                  | DRKYLPE | 2 | 6.48 | 1.07 | 6.93 |
|                       |                   |                  | KPVGYRS | 3 | 6.1 | 1.13 | 6.89 |
|                       |                   |                  | ECPDEHRA | 1 | 6.44 | 1.03 | 6.63 |
|                       |                   |                  | KYLPETPR | 2 | 6.16 | 1.05 | 6.47 |
|                       |                   |                  | NS3 protein | NP_775670.1 | YPKCKNGD | 3 | 6.45 | 1.31 | 8.45 |
|                       |                   |                  | PKPCKGID | 3 | 6.15 | 1.34 | 8.24 |
|                       |                   |                  | PPKPCKC | 2 | 5.96 | 1.33 | 7.93 |
|                       |                   |                  | EYPCKNG | 3 | 6.45 | 1.22 | 7.87 |
|                       |                   |                  | DTPSPKPC | 1 | 5.9 | 1.33 | 7.85 |
|                       |                   |                  | NS5 protein | NP_775674.1 | HKDPEHPY | 1 | 7.23 | 1.16 | 8.39 |
|                       |                   |                  | GKENVVDY | 3 | 6.15 | 1.14 | 7.01 |
|                       |                   |                  | PYVGQED | 3 | 6.31 | 1.11 | 7 |
|                       |                   |                  | FYKPEPS | 1 | 5.84 | 1.17 | 6.83 |
|                       |                   |                  | CGRGWSY | 3 | 5.27 | 1.29 | 6.8 |
that the T-cell epitopes FAFRDLCIVYR and RREVYDFAF or their mixture could be considered for vaccine formulation and development. Moreover, another potential T-cell epitope positioning at 65–76 amino acids was also identified as a potential peptide vaccine candidate (Khan et al., 2018).

Human coronavirus (HCoV) has been reported to cause pneumonia as well as some diseases of the respiratory and the gastrointestinal tracts in human. For developing peptide vaccines against this virus, Oany et al. (2014) identified the epitopes in spike proteins that was suggested for boosting immunological response within human body against HCoV. From the study, it was evident that the B-cell epitope positioned at 88–94 amino acids and the T-cell epitope KSSTGFVYF had the ability for designing a peptide vaccine (Oany et al., 2014).

Ebola virus disease (EVD) is considered to be one of the deadly viral diseases affecting human beings. Epitope-based peptide vaccine formulation against EVD using reverse vaccinology approach was reported, wherein the potential T-cell epitopes viz., RRTRRE, RRKRRD, KTGKKG and DEDEDE and the potential B-cell epitopes viz., HLGLDDQ, PDYDDCH, QPKCNPN, DQEKKIL, SHYEPPN, DYDDCHS, PTSPPQD and EYTYPDS were identified from the viral surface proteins (Chakraborty, 2014).

5. Conclusion

The present study suggested that a multi-epitope-based peptide vaccine against JEV could be developed by combining the promising B-cell and T-cell epitopes found in E, prM, NS1, NS3 and NS5 proteins. In order to design a peptide vaccine, the first criterion is to select the epitopes possessing high antigenicity scores. Out of 25 T-cell epitopes examined in five proteins of JEV, eight epitopes were identified to possess high antigenicity scores. These epitopes were EKRADS, KRSRRS, SKSRRR, DPEEDV, EDCGKR, KECPDE and KREKCP. The epitope EKRADS possessed low immunogenicity score and so, it was excluded from further analysis. The remaining seven epitopes possessed high immunogenicity and hydrophilicity values in addition to the desired Boman index value. On the basis of total net charges, three epitopes, i.e. DPEEDV, EDGKGR and KECPDE were excluded from the study as these might not bind with the virus. We concluded that four T-
cell epitopes, viz. KRADSS, KRSRRS, SKRSRR and KREKKP possess the potential to be used in epitope-based peptide vaccine formulation against JEV.

Among 25 octapeptide B-cell epitopes, seven epitopes namely DRYKYLPE, KPVGRYRS, PKPCSKGD, PSPKPCSK, DTPSPKPC, HKDPEHPY and FYKPSEPS were estimated to possess high antigenicity scores. Only one epitope PKPCSKGD was identified with excessive immunogenicity, hydrophilicity as well as Boman index value. This B-cell epitope could be used in formulating the peptide vaccine.

Pharmaceutical companies could initiate efforts to synthesize a multi-epitope-loaded peptide vaccine by combining the promising four T-cell epitopes and one B-cell epitope in varying proportions with a strong adjuvant or carrier protein. The peptide vaccine could be administered in JEV affected persons following proper clinical trials to ensure its safety and efficacy and might prevent the spread of JEV by raising immunity in human.

In view of the endless struggle between human and JEV in evolutionary context, it is advisable to construct different sets of peptide vaccines comprising the epitopes in varied combinations. To build up a continuing resistance against JEV through vaccination, the temporal and spatial deployment strategy (over time and space) of vaccine administration could be followed using different peptide vaccine sets in the countries frequently affected by JEV.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.meegid.2019.104106.

**Declaration of Competing Interest**

Authors declare no conflict of interest in the manuscript.

**Acknowledgement**

The authors are grateful to Assam University, Silchar, Assam, India for providing necessary facilities to carry out this research work. Further, the research work is dedicated to those great souls who died of JEV due to lack of proper medication and affordable medical facility.

**References**

Allison, S.L., Schalich, J., et al., 2001. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J. Virol. 75 (9), 4268–4275.

Baig, S., Fox, K.K., et al., 2013. Japanese encephalitis surveillance and immunization—Asia and the Western Pacific, 2012. MMWR Morb. Mortal. Wiky Rep.
Khan, A., Junaid, M., et al., 2018. Computational identification of vaccine targets for Japanese encephalitis virus. Virology 538, 3–6.

Burke, D.S., Leake, C.J., 1988b. Japanese encephalitis. The Arboviruses 3, 63–276.

Chambers, T.J., Hahn, C.S., et al., 1990. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44 (1), 649–688.

Chou, P.Y., Fasman, G.D., 1978. Empirical predictions of protein conformation. Annu. Rev. Biochem. 47 (1), 251–276.

Kyte, J., Doolittle, R.F., 1982. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157 (1), 105–132.

Konishi, E., Pincus, S., et al., 1992. Mice immunized with a subviral particle containing flavivirus NS1 protein from cells expressing NS1 cDNA. Virology 177 (2), 470–476.

Fischer, M., Hills, S., et al., 2010. Japanese Encephalitis Vaccines; Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Halstead, S.B., Thomas, S.J., 2010. Japanese encephalitis: new options for active immunization. Clin. Infect. Dis. 50 (8), 1155–1167.

Fan, W., Mason, P.W., 1990. Membrane association and secretion of the Japanese encephalitis virus NS1 protein from cells expressing NS1 cDNA. Virology 177 (2), 470–476.

Fischer, M., Hills, S., et al., 2008. Japanese encephalitis prevention and control: advances, challenges, and new initiatives. In: Emerging Infections 8. American Society of Microbiology, pp. 93–124.

Fischer, M., Hills, S., et al., 2010. Japanese Encephalitis Vaccines; Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Halstead, S., Jacobson, J., 2008. Japanese encephalitis vaccines. In: Plotkin, S.A., Orenstein, W.A., Offit, P.A. (Eds.), Vaccines. Elsevier, Philadelphia.

Hegde, N.R., Gore, M.M., 2017. Japanese encephalitis vaccines: immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease. Human Vaccin. Immunother. 13 (6), 1320–1337.

Hopp, T.P., Woods, K.R., 1981. Prediction of protein antigenic determinants from amino acid sequences. Proc. Natl. Acad. Sci. 78 (6), 3824–3828.

Koelle, R.M., Aberle, J.H., et al., 2004. Mimicking live vaccines: subviral particle containing the Japanese encephalitis virus μM and E proteins are protected from lethal JEV infection. Virology 188 (2), 714–720.

Kori, P., Sajjan, S.S., et al., 2015. In silico prediction of epitopes for Chikungunya viral envelope protein. J. Pharmaceut. Invest. 45 (6), 579–591.

Kuhn, R.J., Zhang, W., et al., 2002. Structure of dengue virus: implications for flavivirus organization, maturation and fusion. Cell 108 (5), 717–725.

Kyte, J., Doolittle, R.F., 1982. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157 (1), 105–132.

Lafuente, E.M., Reche, P.A., 2009. Prediction of MHC-peptide binding: a systematic and comprehensive overview. Curr. Pharm. Des. 15 (28), 3209–3220.

Li, Y., Xu, M., et al., 2009. Evaluation of murine bone marrow-derived dendritic cells loaded with inactivated virus as a vaccine against Japanese encephalitis virus. Vaccine 27 (43), 6004–6010.

Mackenzie, J.S., Williams, D.T., et al., 2006. Japanese encephalitis virus: the geographic distribution, incidence, and spread of a virus with a propensity to emerge in new areas. Perspect. Med. Virol. 16, 201–268.

Marin, M., Zanotto, P., et al., 1995. Phylogeny of TYU, SRE, and CFA viruses: different evolutionary rates in the genus Flavivirus. Virology 206 (2), 1133–1139.

Monath, T., Heinz, F., et al., 1996. Flaviviruses. In: Fields Virology. 1. pp. 961–1034.

Oany, A.R., Emran, A.A., et al., 2014. Design of an epitope-based peptide vaccine against spike protein of human coronavirus: an in silico approach. Drug Des. Develop. Ther. 8, 1139.

Ooi, M.H., Lewthwaite, P., et al., 2008. The epidemiology, clinical features, and long-term prognosis of Japanese encephalitis in central sarawak, malaysia, 1997–2005. Clin. Infect. Dis. 47 (4), 458–468.

Organization, W. H, 2015. Japanese encephalitis vaccine (WHO position paper—February 2015). In: Weekly Epidemiological Record= Revêle Épidémiologique Hebdomadaire. 90(09), pp. 69–88.

Oya, A., 1988. Japanese encephalitis vaccine. Pediatr. Int. 30 (2), 175–184.

Paul, W., Moore, P., et al., 1993. Outbreak of Japanese encephalitis on the island of Saipan, 1990. J. Infect. Dis. 167 (5), 1053–1058.

Peeples, T., Hoffert, J.D., et al., 2011. NIHBI-ASHdesigner: an online tool for design of peptide-directed antibodies. Am. J. Phys. Cell Phys. 302 (1), C154–C164.

Porterfield, J.S., 1995. Exotic Viral Infections. Chapman & Hall Medical Oxford.

Rice, C., 1996. Flaviviridae: the viruses and their replication. In: Fields, B.N., Knipe, D.M., Howley, P.M. (Eds.), Fields Virology. Vol. 1 Lippincott-Raven Publishers, Philadelphia.

Rice, C.M., Lenches, E.M., et al., 1985. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229 (4715), 726–733.

Rinaldo, C.D., Telford, J.L., et al., 2009. Vaccination in the genome era. J. Clin. Invest. 119 (9), 2515–2525.

Sakib, M.S., Islam, M., et al., 2014. Prediction of epitope-based peptides for the utility of vaccine development from fusion and glycoprotein of nipah virus using in silico approach. Adv. Bioinforma. 2014.

Skowronskys, M., Toth, L., 2016. Peptide-based synthetic vaccines. Chem. Sci. 7 (2), 842–854.

Solomon, T., 1997. Viral encephalitis in southeast Asia. Neuro. Infect. Epidemiol. 2, 191–199.

Solomon, T., Vaughn, D., 2002. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. In: Japanese Encephalitis and West Nile Viruses. Springer, pp. 171–194.

Solomon, T., Kneen, R., et al., 1998. Poliomylitis-like illness due to Japanese encephalitis virus. Lancet 351 (9109), 1094–1097.

Solomon, T., Dung, N.M., et al., 2000. Japanese encephalitis. J. Neurol. Neurosurg. Psychiatry 68 (4), 405–415.

Solomon, T., Dung, N.M., et al., 2002. Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis. Brain 125 (5), 1084–1093.

Solomon, T., Ni, H., et al., 2003. Origin and evolution of Japanese encephalitis virus in Southeast Asia. J. Virol. 77 (5), 3991–3998.

Tsai, T., 1997. Factors in the changing epidemiology of Japanese encephalitis and West Nile virus infections. In: Japanese Encephalitis and West Nile Viruses. Springer, pp. 171–194.

Tsai, T., Kneen, R., et al., 1998. Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet 351 (9109), 1094–1097.

Tantray, V.G., Chait, V., et al., 2014. A new vaccine candidate using reverse vaccinology for vibrio Cholera0395 in cholera disease. Int. J. Innovat. Res. Stud. 3 (5).

Tantray, V.G., Chait, V., et al., 2014. A new vaccine candidate using reverse vaccinology for vibrio Cholera0395 in cholera disease. Int. J. Innovat. Res. Stud. 3 (5).

Weiss, A., Littman, D.R., 1994. Signal transduction by lymphocyte antigen receptors. Cell 76 (2), 263–274.

Weitstoy, E., Brinton, M., et al., 1985. In: Livov, D.K., Porterfield, J.S., Russell, P.K., Trent, D.W. (Eds.), Flaviviridae Intervirology. 24. pp. 183–226.

Yadav, G., Rao, R., et al., 2017. Computational modeling and analysis of prominent T-cell epitopes for assisting in designing vaccine of ZIKA virus. J. App. Pharmaceut. Sci. 7 (10), 119–122.

Zanotto, P., Gould, E.A., et al., 1996. Population dynamics of flavivirus gene expression and evolution. Science 229 (4715), 726–733.

Zanotto, P., Gould, E.A., et al., 1996. Population dynamics of flavivirus gene expression and evolution. Science 229 (4715), 726–733.